Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 56, 2021 - Issue 8
Submit an article Journal homepage
158
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis

Li Xinga Department of Gastrointestinal Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
,
Hai-Tao Lvb Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
,
San-Guang Liub Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
,
Wen-Bin Wangb Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
,
Teng-Fei Zhangb Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
,
Jian-Hua Liub Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China
&
Wei Bianb Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, PR ChinaCorrespondence[email protected]
 show all
Pages 914-919 | Received 22 Oct 2020, Accepted 17 Mar 2021, Published online: 24 Jun 2021

References

  • Sohal DP, Shrotriya S, Abazeed M, et al. Molecular characteristics of biliary tract cancer. Crit Rev Oncol Hematol. 2016;107:111–118.
  • Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194–e203.
  • Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24(4):871–884.
  • Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45(6):856–867.
  • Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
  • Furusato B, Mohamed A, Uhlen M, et al. CXCR4 and cancer. Pathol Int. 2010;60(7):497–505.
  • Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879–894.
  • Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119(9):2026–2029.
  • Kim J, Connelly KL, Unterwald EM, et al. Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats. Brain Behav Immun. 2017;62:30–34.
  • Zhou Z, Liu T, Sun X, et al. CXCR4 antagonist AMD3100 reverses the neurogenesis promoted by enriched environment and suppresses long-term seizure activity in adult rats of temporal lobe epilepsy. Behav Brain Res. 2017;322:83–91.
  • Taromi S, Kayser G, Catusse J, et al. CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget. 2016;7(51):85185–85195.
  • Fontanella R, Pelagalli A, Nardelli A, et al. A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. Cancer Lett. 2016;370(1):100–107.
  • Muralidharan R, Panneerselvam J, Chen A, et al. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015;22(12):581–590.
  • Zhao S, Wang J, Qin C. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 2014;33:103.
  • Mayr C, Neureiter D, Pichler M, et al. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: potential drug synergism with gemcitabine. Mol Med Rep. 2015;12(2):2247–2252.
  • Wachter J, Neureiter D, Alinger B, et al. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012;8(1):15–29.
  • Kiesslich T, Neureiter D, Alinger B, et al. Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and d proliferation. Photochem Photobiol Sci. 2010;9(5):734–743.
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
  • Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.
  • Bonomi A, Sordi V, Dugnani E, et al. Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells. Cytotherapy. 2015;17(12):1687–1695.
  • Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009;21(3):761–767.
  • Kulbe H, Hagemann T, Szlosarek PW, et al. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 2005;65(22):10355–10362.
  • Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359(3):716–722.
  • Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Exp Rev Gastroenterol Hepatol. 2010;4(4):395–397.
  • Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–398.
  • Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681.
  • Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010;103(11):1671–1679.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.